CUTIA-B: CU-40102 (topical finasteride spray) has received marketing approval from the National Medical Products Administration

CUTIA-B announced that its CU-40102 (topical finasteride spray) has received marketing approval from the National Medical Products Administration of China, becoming the world's first topical finasteride for the treatment of androgenetic alopecia. The drug works by inhibiting the conversion of testosterone to dihydrotestosterone in the scalp, providing a more convenient method of administration and reducing systemic drug exposure. This approval is based on the results of a Phase III clinical trial conducted in China, which showed that CU-40102 is effective and well-tolerated. The product will enhance the group's presence in the field of dermatological treatments